tirzepatide acetate | LY3298176 | GIP/GLP-1 Inhibitor Mounjaro (Tirzepatide) Injection 7.5 mg/0.5

This is particularly important if you have pre-existing kidney conditions, diabetes, or cardiovascular disease, as these factors may influence the safety profile of combining these substances

POTENTIAL APPLICATIONS IN OTHER INFLAMMATORY CONDITIONS Studies suggest possible therapeutic roles influencing chronic respiratory conditions, joint inflammation, and other immune system disorders

What makes CagriSema unique: Unlike adding cagrilintide to tirzepatide (unstudied, risky), or using either peptide alone (effective but limited to 10-15% weight loss), CagriSema combines semaglutide's proven GLP-1 efficacy with cagrilintide's distinct amylin mechanism

These findings are from animal models and cell culture studies